Inactive Instrument

Highlights Reshape Lifesciences Inc Nasdaq

Equities

US7611234052

Highlights

Unlock all the news: Be the first to know and act before the market!

ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q1 Revenue $1.9M, vs. Street Est of $2.1M	05-15	MT
ReShape Lifesciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
ReShape Lifesciences Gets US Patent for Intragastric Balloon Weight-Loss System	03-28	MT
ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System	03-28	CI
Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex	02-22	CI
ReShape Lifesciences®? Receives FDA PMA Supplement Approval for Its Next-Generation Lap-Band®? 2.0 FLEX	12-12	CI
ReShape Lifesciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q3 Revenue $2.2M, vs. Street Est of $2.4M	11-08	MT
ReShape Lifesciences Inc. Signs Exclusive License Agreement With Biorad Medisys for Obalon(R) Gastric Balloon System	21/09/23	CI
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q2 Revenue $2.3M, vs. Street Est of $2.6M	07/08/23	MT
ReShape Lifesciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/08/23	CI
Reshape Lifesciences Inc. Signs Preferred Partner Agreement with Hive Medical for Lead Optimization Software	29/06/23	CI
ReShape Lifesciences Inc. Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device at the ASMBS 2023 Annual Meeting	28/06/23	CI
ReShape Lifesciences Files US FDA Premarket Approval Supplement Application for Lap-Band 2.0; Shares Surge After Hours	26/06/23	MT
ReShape Lifesciences Submits FDA PMA Supplement Application for the Next-Generation Lap-BandÂ® 2.0	26/06/23	CI
ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q1 Revenue $2.3M, vs. Street Est of $2.51M	15/05/23	MT
ReShape Lifesciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/04/23	CI
North American Morning Briefing : Subdued Open -2-	17/04/23	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Reshape Lifesciences Inc Nasdaq

Equities

US7611234052

Highlights

Filters